Thus, all patients with high levels of HER2 expression, independently of the breast cancer subtype to which they were classified, can benefit from targeted anti-HER2 therapies, as well as any patients with another type of solid tumor over-expressing HER2. This evidence concerns the gene ERBB2 and breast carcinoma.